The short lifespan and systemic toxicity of IL-2 are major limitations for IL-2-based cancer immunotherapy. To overcome these hurdles, a single dose of a pressure-fused biomineral tablet is shown to safely support a two-phase IL-2 release, leading to weeks-long intratumoral retention of the cytokine to promote anti-tumor T cell immunity.
- Jianping Liu
- Xiaoyuan Chen